2nd Sep 2015 10:35
LONDON (Alliance News) - AstraZeneca PLC on Wednesday said its biologics research and development unit MedImmune has signed a deal with Japan-based pharmaceutical company Daiichi Sankyo Co Ltd granting the latter an exclusive licence to develop and commercialise the FluMist Quadrivalent product in Japan.
FTSE 100-listed AstraZeneca said FluMist Quadrivalent is a flu vaccine administered via a nasal spray. Phase 3 safety and efficacy trials were conducted on the product in the 2014-15 flu season in Japan and a regulatory submission for the project is being prepared.
Under the deal, Daiichi Sankyo will pay AstraZeneca an upfront fee with subsequent development milestones and sales-related payments post the launch of the product, though no specific financial details were disclosed.
Shares in AstraZeneca were up 0.9% to 4,069.00 pence on Wednesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca